Reid Robison

Add links
From Wikipedia, the free encyclopedia
Reid Robison
Born (1976-09-11) September 11, 1976 (age 47)
Hinsdale, Illinois, U.S.
CitizenshipUnited States of America
Alma materUniversity of Utah (M.D.)
University of Utah (M.B.A.)
Brigham Young University (B.S.)
Scientific career
FieldsPsychiatry
Mental Health
Psychedelic Therapy
Websitehttps://www.reidrobison.com/

Reid Robison (born September 1976 in Illinois) is an American board-certified psychiatrist known primarily for his work with psychedelic medicines. As an early adopter and researcher of the use of ketamine in psychiatry, Robison has made significant contributions to ketamine-assisted psychotherapy (KAP) and other treatment modalities using ketamine for mental health conditions.[1][2] He previously served as coordinating investigator for a study on MDMA-assisted psychotherapy for eating disorders, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), and he continues to lead research and psychiatric clinical trials involving psychedelics. To date, Robison has guided thousands of ketamine-assisted therapy sessions and Spravato dosing sessions. He currently serves as Medical Director of Center for Change,[3] an eating disorder treatment center in Utah, and Chief Clinical Officer of Numinus, a Vancouver-based mental health company focused on psychedelic research and treatments.[4] Robison is an adjunct professor at both the University of Utah and Brigham Young University.

Education and early life[edit]

Robison was born in 1976 near Chicago and grew up living in Toronto, Canada.[5] He returned to the United States for college and received a B.S. in Neuroscience from Brigham Young University, in 2001, after which he attended the University of Utah School of Medicine in Salt Lake City, UT. Upon earning a dual M.D./M.B.A in 2005, he completed psychiatry residency training at the University of Utah, followed by fellowship training in genetics and bioinformatics at the University of Utah.

Career and research[edit]

After his fellowship, Robison held a faculty position at the University of Utah School of Medicine from 2009 to 2011. Here, he served as the Associate Director of the Mood Disorders Clinic and co-directed the Psychiatric Molecular Genetics lab where he focused his research primarily on the genetic associations of autism, and also contributed to the discovery of Ogden Syndrome, a rare disease found using next-generation sequencing technology.[6] During his time as faculty within the Department of Psychiatry he also led global health initiatives and guided trainees during trips to Haiti, Ghana and refugee camps along the Thai/Burma border.[5]

Early in his career, Robison founded the Polizzi Foundation, a free clinic based in Salt Lake City offering mental health services to the uninsured.[7] He also co-founded Clinical Methods, a center for clinical trials, with a Clark W Johnson MD, his medical school colleague and business partner. Clinical Methods was acquired by CRI-Lifetree in 2012 and later PRA Health Sciences.

Robison has also been closely involved with Intermountain Healthcare, the largest healthcare provider in the mountain west region of the United States. Robison set up the Consult-Liaison Service at Intermountain Medical Center, Intermountain’s flagship hospital, to provide psychiatric consults to the emergency department and medical floors. After conducting his first research study of ketamine in 2011, he went on to create a ketamine program for treatment-resistant depression at Intermountain’s IV Therapy Center. In 2012, he obtained a grant to study ketamine for depression from the Intermountain Research & Medical Foundation.[8]

In 2012, Robison and computational biologist Kai Wang co-founded Tute Genomics, a personalized medicine software company which sought to increase practice of genomic medicine. In 2016, Tute Genomics was acquired by PierianDx.[9] Robison currently sits on the board of directors. Robison is recognized for speeding up genomic data transfer and analysis through the use of Google Fiber.[10]

Later, Robison and a colleague co-founded Cedar Psychiatry,[11][8] a network of outpatient mental health clinics offering ketamine therapy, transcranial magnetic stimulation (TMS), medication management, and psychotherapy, and Cedar Clinical Research[12] in 2018. At Cedar Clinical Research, Robison led the Utah site for the pivotal IV ketamine study of treatment-resistant depression by Janssen,[13] leading up to the company’s FDA-approval of Spravato (esketamine) via breakthrough therapy designation in 2019.[14] After the companies were acquired in 2020, by Novamind,[15] a Canadian company endeavoring to bring psychedelic medicine into the mental health field, Robison was appointed as the Chief Medical Officer.[16] Upon the acquisition of Novamind by Numinus,[17] another Canadian-based company with expertise in psychedelic medicine, Robison became the Chief Clinical Officer of Numinus.[4] In this role, Robison continues to oversee the ketamine therapy practice at Cedar Psychiatry for treating depression, PTSD, eating disorders, OCD and other mental health conditions.

Robison also continues in his as Medical Director of Center for Change,[3] an eating disorder treatment center in Utah.

Awards and recognition[edit]

  • In 2014, Robison was named one of the Utah Venture Entrepreneur Forum peak 100 entrepreneurs of the year.[18]
  • In 2015, Robison was named one of the top 40 healthcare transformers of the year,[19]
  • In 2020, Robison was named Best Psychiatrist in Utah.[20]

Yoga[edit]

Robison is a certified Yoga instructed and completed his training under Sri Dharma Mittra in New York City. He often speaks and writes about yoga and mindfulness for mental health.[21]

References[edit]

  1. ^ "Ketamine Expert Dr. Reid Robison On Clinical Trials, Ketamine For Eating Disorders, And Novamind's Plans For Growth". The Dales Report. 26 January 2022. Retrieved 27 January 2022.
  2. ^ "Off-Label Ketamine, Spravato and the Future of Ketamine Treatment for Depression". Microdose. 5 July 2021. Retrieved 26 July 2021.
  3. ^ a b "Medical Director, Center for Change". Center for Change. Retrieved 20 June 2021.
  4. ^ a b "Numinus completes acquisition of Novamind and announces executive appointments". PR Newswire. Cision. Retrieved 10 June 2022.
  5. ^ a b "Adventures in Psychiatry". ReidRobison.com. Retrieved 12 November 2021.
  6. ^ Rope, Alan F.; Wang, Kai; Evjenth, Rune; Xing, Jinchuan; Johnston, Jennifer J.; Swensen, Jeffrey J.; Johnson, W. Evan; Moore, Barry; Huff, Chad D.; Bird, Lynne M.; Carey, John C.; Opitz, John M.; Stevens, Cathy A.; Jiang, Tao; Schank, Christa; Fain, Heidi Deborah; Robison, Reid; Dalley, Brian; Chin, Steven; South, Sarah T.; Pysher, Theodore J.; Jorde, Lynn B.; Hakonarson, Hakon; Lillehaug, Johan R.; Biesecker, Leslie G.; Yandell, Mark; Arnesen, Thomas; Lyon, Gholson J. (July 2011). "Using VAAST to Identify an X-Linked Disorder Resulting in Lethality in Male Infants Due to N-Terminal Acetyltransferase Deficiency". The American Journal of Human Genetics. 89 (1): 28–43. doi:10.1016/j.ajhg.2011.05.017. PMC 3135802. PMID 21700266.
  7. ^ "SelectHealth Announces This Year's Select 25 Award Winners". selecthealth.org. Retrieved 30 May 2015.
  8. ^ a b "Dr. Reid Robison - Founder Of Cedar Psychiatry & Medical Director Focusing On Ketamine Treatment & MDMA Therapy For Eating Disorders". Apple Podcasts. Retrieved 7 April 2021.
  9. ^ "PierianDx Acquires Tute Genomics". PierianDx. Retrieved 7 December 2021.
  10. ^ "How Google Fiber is changing the game for genomics". medium.com. 23 January 2015. Retrieved 30 May 2015.
  11. ^ "Cedar Psychiatry". Cedar Psychiatry. Retrieved 30 December 2020.
  12. ^ "Cedar Clinical Research". Cedar Clinical Research. Retrieved 24 December 2020.
  13. ^ "Spravato Trials". Lucid News. 26 October 2021. Retrieved 30 May 2022.
  14. ^ "Spravato FDA Approval". U.S. Federal Drug Administration. 5 March 2019. Retrieved 16 May 2022.
  15. ^ "Our team". novamind.ca. Retrieved 29 December 2020.
  16. ^ "Novamind Appoints Dr. Reid Robison as Chief Medical Officer". Novamind. Retrieved 16 October 2020.
  17. ^ "Numinus". Numinus. Retrieved 19 June 2022.
  18. ^ "2014 Peak 100 Winners". uvef.com. Retrieved 30 May 2015.
  19. ^ "The Top 40 Healthcare Transformers". mmm-online.com. 4 January 2015. Retrieved 30 May 2015.
  20. ^ Copperfield Publishing. "Best of Utah Body & Mind 202". Issuu. Retrieved 16 February 2020.
  21. ^ "9 Ways That Science Has Yoga's Back". Elephant Journal. Retrieved 13 September 2017.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Reid_Robison&oldid=1123100607"